A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)-Reference-Cited by-同舟云学术

A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)

Published:2017-07-03 Issue:1 Volume:17 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Bandak Mikkel^ORCID,Jørgensen Niels,Juul Anders,Lauritsen Jakob,Kreiberg Michael,Oturai Peter Sandor,Helge Jørn Wulff,Daugaard Gedske

Funder

Kræftens Bekæmpelse

Dansk Kræftforsknings Fond

Rigshospitalet

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-017-3456-5.pdf

Reference32 articles.

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer [Internet]. 2010 [cited 2016 Oct 23]; 127:2893–917. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21351269 .

2. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. [Internet]. 2007 [cited 2016 Sep 8];8:784–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17714993 .

3. Nord C, Bjøro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. [Internet]. 2003 [cited 2013 Mar 27];44:322–8. Available from: http://dx.doi.org/10.1016/S0302-2838(03)00263-X .

4. Wiechno P, Demkow T, Kubiak K, Sadowska M, Kamińska J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol. [Internet]. 2007 [cited 2016 Aug 18];52:1448–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17544206 .

5. Sprauten M, Brydøy M, Haugnes HS, Cvancarova M, Bjøro T, Bjerner J, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol. [Internet]. 2014 [cited 2016 Apr 21];32:571–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24419125 .

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency;Clinical Genitourinary Cancer;2023-08

2. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors – results from a randomized double-blind trial;Acta Oncologica;2023-05-07

3. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention);Clinical Genitourinary Cancer;2022-10

4. Effect of Testosterone Replacement Therapy on Quality of Life and Sexual Function in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency: Results From a Randomized Double-blind Trial;Clinical Genitourinary Cancer;2022-08

5. Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2022-08